The involvement of rare cancer patients in clinical research

New drugs on the CML horizon; choosing the correct therapies

The evolving landscape in the management of CML

Maintenance therapy in multiple myeloma; the way forward

A new treatment paradigm in multiple myeloma

Advances with bendamustine in multiple myeloma from EHA 2012

Advances in multiple myeloma from EHA 2012

Advances in multiple myeloma from EHA 2012; bortezomib and beyond

Dasatinib vs. imatinib first-line in CML; new study data

The evolving landscape in CML management

AZA in MDS, and managing the older MDS patient

Lenalidomide in low-risk MDS del(5q)